Canaccord Genuity Downgrades Akero Therapeutics (AKRO) to Hold Oct 9, 2025 12:12PM
Akero Therapeutics (AKRO) PT Raised to $73 at Canaccord Genuity Jan 28, 2025 06:35AM
Canaccord Genuity Reiterates Buy Rating on Akero Therapeutics (AKRO) Jun 12, 2024 07:44AM
Akero Therapeutics (AKRO) PT Lowered to $56 at Canaccord Genuity May 13, 2024 06:29AM
Akero Therapeutics (AKRO) declines after efruxifermin NASH trial readout disappoints; Is it time to buy? Oct 10, 2023 08:26AM


Oct 10, 2023 08:21AM Canaccord on Akero Therapeutics (AKRO): 'We would be strong buyers on this weakness'
Nov 4, 2022 07:00AM Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
Nov 4, 2022 07:00AM Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
Sep 19, 2022 04:01PM Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Sep 19, 2022 04:01PM Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Sep 15, 2022 05:50AM Akero Therapeutics (AKRO) Prices Upsized 7.69M Share Offering at $26/sh
Sep 14, 2022 08:07PM Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
Sep 14, 2022 08:07PM Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
Sep 13, 2022 04:01PM Akero Therapeutics (AKRO) Announces Proposed $175M Share Offering
Sep 13, 2022 04:01PM Akero Therapeutics Announces Proposed Public Offering of Common Stock
Sep 13, 2022 04:01PM Akero Therapeutics Announces Proposed Public Offering of Common Stock
Mar 18, 2021 08:58AM Akero Therapeutics (AKRO) PT Lowered to $46 at Canaccord Genuity
Feb 10, 2020 05:34AM Canaccord Genuity Starts Akero Therapeutics (AKRO) at Buy